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ABSTRACT 
Under resting conditions, the failing heart shifts fuel use towards greater glucose and lower 
free fatty acids oxidation.  We hypothesized that chronic metabolic abnormalities in patients 
with dilated cardiomyopathy (DCM) are associated with the absence of the normal increase in 
myocardial glucose uptake and maintenance of cardiac mechanical efficiency in response to 
pacing  stress.  In  10  DCM  and  in  6  control  subjects,  we  measured  coronary  flow  by 
intravascular  ultrasonometry  and  sampled  arterial  and  coronary  sinus  blood.  Myocardial 
metabolism was determined at baseline, during atrial pacing at 130 bpm, and at 15 minutes of 
recovery, by infusing 
3H-oleate and 
13C-lactate and measuring transmyocardial artero-venous 
differences of oxygen and metabolites. At baseline, DCM patients showed depressed coronary 
flow,  reduced  uptake  and  oxidation  of  FFA  and  preferential  utilization  of  carbohydrates. 
During  pacing  glucose  uptake  increased  by  106%  in  controls,  but  did  not  change  from 
baseline in DCM.  Lactate release increased by 122% in DCM but not in controls. Cardiac 
mechanical efficiency in DCM was not different compared to controls at baseline, but was 
34% lower during stress.  Fatty acid uptake and oxidation did not change with pacing in either 
group.  Our results show that in DCM there is preferential utilization of carbohydrates which 
is associated with reduced flow and oxygen consumption at rest and an impaired ability to 
increase  glucose  uptake  during  stress.  These  metabolic  abnormalities  might  contribute  to 
progressive cardiac  deterioration and represent a target for therapeutic strategies aimed at 
modulating cardiac substrate utilization.  
Keywords:  Metabolism ; Cardiomyopathies ; Microcirculation
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Introduction 
Fatty acids provide 60 to 90% of the energy necessary to sustain contractile function in 
the  resting  fasting  state,  with  the  remainder  coming  from  glucose  and  lactate  oxidation.  
During  acute  cardiac  stress,  such  as  pacing  or  exercise,  the  healthy  human  heart  rapidly 
increases glucose and lactate uptake, with a relative decline in free fatty acid (FFA) uptake (1, 
3-4, 9).
  Clinical and animal studies suggest that this response is advantageous: it increases 
myocardial metabolic efficiency, since carbohydrates are a more efficient substrate than lipids, 
generating  more  contractile  power  for  any  given  rate  of  myocardial  oxygen  consumption 
(MVO2) (20, 29, 31).
 
Dilated  cardiomyopathy  (DCM) is often characterized by reduced FFA uptake and 
oxidation, and accelerated glycolysis and glucose oxidation under resting conditions (7, 21, 
29,  31).    This  metabolic  shift  may  act  to  optimize  the  limited  oxidative  capacity  of 
cardiomyopathic hearts resulting from impairment of mitochondrial function (28), and/or ATP 
transfer from mitochondria to the contractile apparatus (30), or reduced myocardial perfusion 
and flow reserve due to coronary microvascular dysfunction (16-17).  Little is known about 
myocardial metabolism in DCM patient under conditions of increased workload. Factors that 
differentiate DCM from healthy conditions (altered metabolic phenotype, limited oxidative 
capabilities,  reduced  flow  availability,  etc.)  might  limit  the  ability  of  the  dysfunctional 
myocardium to adapt to acute stress.   The myocardial metabolic and flow response to acute 
atrial pacing stress has been extensively investigated in patients with syndrome X(1, 3) and 
coronary artery disease (CAD) (23-24, 39), but not in DCM patients.  This information is 
clinically relevant, since metabolic modulators, such as agents that partially inhibit myocardial 
FFA  oxidation,  improve  symptoms  of  stress-induced  ischemia  in  angina  patient  (32)  and 
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ventricular function in patients with ischemic cardiomyopathy (2, 13, 31, 37) but the rationale 
for their potential use in heart failure and DCM is still under debate. 
The  purpose  of  the  present  investigation  was  to  assess  the  relationships  between 
cardiac substrate metabolism, ventricular dysfunction, and coronary blood flow at rest and in  
response to acute pacing stress in DCM patients and in a control group of patients with normal 
coronary  arteries,  left  ventricular  mass  and  volume.  We  hypothesized  that  the  chronic 
metabolic  abnormalities  in  DCM  observed  at  rest  are  associated  with  the  absence  of  the 
normal  response  to  pacing  stress,  namely  an  increase  in  myocardial  glucose  uptake  and 
maintenance  of  cardiac  mechanical  efficiency.    Coronary  hemodynamics  and  myocardial 
substrate metabolism were measured directly by cardiac catheterization and transmyocardial 
blood sampling using an infusion of  
3H-oleate and 
13C-lactate tracers.  
 
MATERIALS AND METHODS 
Study population 
From October 2003 to May 2006, we enrolled 10 consecutive patients with DCM and 
6 patients with normal LV function (controls), selected among the 329 patients admitted to the 
cardiology  unit  of  the  CNR  Institute  of  Clinical  Physiology  in  Pisa  and  showing  normal 
coronary  arteries  at  angiography.  DCM  patients  were  selected  according  to  the  following 
inclusion  criteria:  age  between  20  and  80  years,  left  ventricular  ejection  fraction  (LVEF) 
<40%,  left ventricular end-diastolic diameter (LVEDD) >56 mm, angiographically normal 
coronary arteries (<50% coronary diameter stenosis). Exclusion criteria were: NYHA class IV, 
previous myocardial infarction, valvular heart disease, actual systemic arterial hypertension, 
myocardial active inflammatory/infective diseases such as myocarditis or pericarditis, current 
cigarette smoking, diabetes, presence of other systemic illnesses, such as neoplasia, renal, 
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hepatic  or  respiratory  failure,  atrial  fibrillation.  Control  patients  underwent  coronary 
angiography for history of angina-like chest pain and/or previous stress tests suspicious for 
myocardial ischemia. Inclusion criteria for control patients were age between 20 and 80 years, 
LVEF >50%, LVEDD <56 mm, angiographically normal coronary arteries (<50% coronary 
diameter reduction) and absence of other cardiovascular or systemic diseases. 
Both groups of patients underwent routine blood tests, ECG, chest X-ray and resting 
2D-Echo. LV function, dimensions and mass were evaluated from 2D-Echo data according to 
standardized protocols (12).  Eight DCM patients were also submitted, within 30 days after 
the catheterization procedure, to positron emission tomography (PET) with 
13N-Ammomia to 
measure specific blood flow per gram of myocardial tissue (ml/min/g) at rest. Specific flow 
was computed according to standardized protocols (17) in the left anterior descending (LAD) 
coronary myocardial territory (5).  
The  study  was  approved  by  the  Local  Ethical  Committee  and  conformed  to  the 
Declaration of Helsinki on human research, and written
 informed consent was obtained on the 
day before cardiac catheterization after complete explanation of the protocol and potential 
risks.      All  coronary-active  drugs,  including  nitrates,  Ca
++-antagonists,   -blockers,  ACE-
inhibitors or statins, were suspended at least 24 hours before catheterization. 
 
Cardiac catheterization 
In the morning, after an overnight fast, all patients were submitted to routine coronary 
angiography  and  definitively  enrolled  after  excluding  the presence of significant  coronary 
stenosis. 
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Cardiac catheterization was performed to measure coronary perfusion pressure, flow 
velocity, and cross-sectional area in the proximal third of the LAD, and the transmyocardial 
artero-venous gradients across the LAD myocardial territory of labelled (L-3-
13C-lactate and 
[9,10-
3H]-oleate) and non-labelled substrates (FFA, glucose and lactate). At the completion of 
diagnostic catheterization, an i.v. bolus of 110 mg L-3-
13C-lactate was administered, followed 
by i.v. continuous infusion of [9,10-
3H]-oleate at 84 µCi/h and L-3-
13C-lactate at 130 mg/h 
allowing a 30 minute equilibration period.  The 
13C-lactate tracer was used to the measure of 
simultaneous lactate uptake and efflux from the myocardium (8, 9, 35) and the 
3H-oleate 
tracer to measure FFA oxidation from the myocardial production of 
3H2O (21).  A 6F guiding 
catheter was placed in the left main coronary ostium through a 7F femoral artery introducer. 
An  intracoronary heparin bolus  (100 U/Kg) was given and a 0.014-in Doppler flow wire 
(FloWire,  Volcano  Corp)  was  advanced  into  the  LAD.  A  2.9  F,  10  MHz  intravascular 
ultrasound (IVUS) catheter (Eagle Eye Gold, Volcano Corp) was passed over the flow wire 
and  positioned  in  the  LAD  immediately  distal  to  the  first  septal  perforating  branch.  The 
Doppler flow wire was positioned two centimeters distal to the tip of the IVUS catheter to 
avoid artefact caused by the catheter wake. The position of the IVUS catheter and flow wire 
was documented by angiography and maintained throughout the study by fluoroscopic control. 
After LAD instrumentation, a 5F catheter was advanced into the coronary sinus, up to the 
great cardiac vein, to withdraw venous blood from the LAD territory; then a unipolar pacing 
catheter was positioned into the right atrium. Due to the complexity of the instrumentation, 5 
additional patients, fulfilling the inclusion criteria but in whom the catheterization procedures 
could not be completed, were excluded from the study. 
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After  calibration,  phasic  and  mean  coronary  perfusion  pressure  (from  the  guiding 
catheter)  and  coronary  flow  velocity  signals  were  continuously  recorded  on  paper  and 
acquired,  together  with  ECG  (leads  DI-DII-DIII),  on  a  personal  computer  equipped  with 
dedicated software. IVUS images were obtained for  30 seconds at each step of the protocol, 
with temporal synchronization with flow velocity signal, and recorded for off-line analysis.  
At  each  step  of  the  protocol,  arterial  and  venous  blood  samples  were  withdrawn 
simultaneously, over 30 seconds, from the femoral artery introducer and the great cardiac 
vein,  and  immediately  processed  for  gas  analysis  and  measurements  of  metabolite 
concentration. 
 
Study protocol 
The  study  protocol  consisted  of  4  steps.  After  the  instrumentation  was  completed 
(about 30 min), continuous monitoring of coronary hemodynamic signals was started and the 
baseline artero-venous sampling was performed (”Baseline”).  Heart rate was increased by 
atrial pacing to 110 bpm for 3 min and to 130 bpm for 3 additional min and artero-venous 
sampling was repeated (”Pacing”). Pacing was then stopped and, 15 min later, a third pair of 
artero-venous samples was withdrawn (”Recovery”). After an additional 15 minutes, when all 
hemodynamic parameters had returned to baseline, an i.v. adenosine infusion was given for 3 
min  unless  it  was  not  clinically  tolerated  or  significant  bradycardia  (HR  <  50  bpm)  or 
hypotension (systolic pressure < 90 mmHg) occurred. Coronary parameters were acquired at 
the end of the third minute of adenosine administration, or just before suspension, and were 
used to estimate coronary flow reserve (Step 4). 
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Data Analysis 
Coronary flow  
Coronary  flow  was  calculated  off-line  by  multiplying  Doppler-derived  mean  flow 
velocity  by  coronary  lumen  cross  sectional  area  measured  by  IVUS  as  described  in Data 
Supplements.  
Coronary  flow  reserve  was  computed  as  adenosine/resting  CBF.  An  estimate  of 
myocardial mechanical efficiency was obtained from rate-pressure product (RPP) and MVO2
measured at each step as follows (see also Data Supplements): 
(RPP/LV mass)/ [MVO2/(0.54*LV mass)] = (RPP*0.54)/ MVO2.
Metabolites 
Blood samples from the femoral artery and the coronary sinus were withdrawn slowly 
in order to avoid hemolysis and potential contamination with right atrial blood. The first 5 mL 
from the coronary sinus catheter were discarded to avoid contamination from either saline or 
blood present into the catheter. Oxygen consumption and metabolite uptake and oxidation 
were measured as previously described (9-10, 26) (see data Supplement). The percent of the 
MVO2 due to FFA or lactate oxidation was calculated as previously described (26).  For 
lactate, it was assumed that 100% of the 
13C-lactate taken up by the heart is oxidized to CO2
(9). 
 
Statistics 
Data  are  presented  as  mean±SEM.  Differences  among  patients  groups  for  discrete 
clinical variables were evaluated by  
2 test. Coronary hemodynamic and metabolic data were 
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compared in each study condition among groups and for different study conditions in the same 
group by two-ways ANOVA followed by Fisher’s exact test. An unpaired t-test was used to 
compare single study conditions between groups when appropriate. P value less than 0.05 was 
considered significant. 
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RESULTS 
 
Characteristics of the study population 
Clinical, functional and biohumoral data are shown in Table 1. The two groups did not 
significantly differ in age or sex.  History of angina-like chest pain was more frequent in 
controls while risk factors were similar in the two groups. Body mass index and the ratio of 
total  triglycerides  over  HDL  cholesterol,  surrogate  measures  of  insulin  resistance  and  the 
metabolic syndrome, did not differ between the two groups.  DCM patients showed reduced 
LV systolic function and an enlarged LV chamber, frequent left bundle branch block, higher 
BNP  and  NT-proBNP  plasma  levels.  However,  DCM  patients  did  not  show  evidence  of 
advanced  heart  failure  (8  of  10  patients  in  NYHA  class  I-II)  or  extensive  sympathetic 
activation (norepinephrine plasma levels were not significantly different between DCM and 
controls). Use of primary cardioactive drugs was not significantly different between the two 
groups except for digoxin and diuretics in DCM patients. 
 
Coronary hemodynamics 
 In one patient in the control group the coronary sinus catheter was displaced into the 
right atrium, thus metabolic measurements were not obtained. In two patients of the DCM 
group pacing rate was maintained at 110 bpm since they did not tolerate higher rate; in one of 
these two and in one other patient i.v. adenosine was not administered as they asked to shorten 
the study. 
Data on coronary hemodynamics during and after pacing stress are summarized in 
Table 2. While heart rate was not significantly different between controls and DCM, coronary 
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mean perfusion pressure, RPP and CBF in the LAD territory were lower in DCM than in 
controls in all the study conditions. From baseline to pacing, heart rate and RPP significantly 
increased in both groups and were restored to baseline levels at recovery. CBF significantly 
increased during pacing only in DCM group and significantly decreased at recovery in the 
control group. 
During intravenous adenosine infusion there was a trend for CBF to remain lower in 
DCM  than  in  controls  (2.18±1.30  vs  3.29±0.89  ml/min/g,  P=0.09),  while  coronary  flow 
reserve was not significantly different between the two groups (3.59±2.53 vs 3.31±1.25, ns). 
 
Myocardial metabolism and energetics 
Baseline arterial concentrations of the major cardiac substrates were not significantly 
different between the two groups (Table 3) and did not significantly change during the study. 
DCM patients showed a significantly lower FFA uptake and oxidation at all time points and 
significantly  higher  glucose  uptake  than  controls  at  baseline  (Figure  1).  During  pacing, 
glucose uptake significantly increased in controls by 106% but did not change in DCM, so 
that it was no longer different between the two groups. The percent net extraction of arterial 
FFA was unaffected by pacing and was similar between groups (Table 4).   On the other hand, 
glucose and lactate extraction were higher in DCM group than Controls.  Glucose extraction 
did not significantly increase during pacing stress in Controls, but decreased significantly in 
the DCM compared to baseline and recovery periods (Table 4). 
Tracer measured myocardial uptake of lactate was not significantly different between 
controls and DCM at baseline and did not show significant changes during stress in both 
groups  (Figure  2).  At  recovery,  it  significantly  decreased  in  controls.  Myocardial  lactate 
release was significantly lower in DCM than in controls at baseline, but during pacing it 
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significantly increased by 122% in DCM and reached the levels similar to controls. Net uptake 
tended to be higher in DCM patients but this difference was not statistically significant. 
Overall, RPP and MVO2 were lower in DCM patients than in controls (Figure 3). 
However, the ratio of RPP to MVO2 (an index of myocardial mechanical efficiency, i.e. work 
performed for a given amount of oxygen consumed) was significantly lower in DCM only 
during stress and at recovery. In fact, during pacing, RPP increased in both groups, but MVO2
increased only in DCM.  At recovery, RPP returned to baseline in both groups but in controls 
MVO2 declined below baseline levels. The analysis of the percent of MVO2 due to oxidation 
of  FFA  showed  that  FFA  contributed  more  to  MVO2 in  controls  than  in  DCM,  and this 
difference was attenuated during pacing stress (Figure 4, upper panel). While the contribution 
of lactate oxidation to MVO2tended to be greater in DCM than in controls, this difference did 
not reach statistical significance (Figure 4, lower panel).  
 
Correlations  between  LV  Remodelling,  Metabolism,  Energetics  and  Coronary  Blood 
Flow.  
There  was  a  strong  inverse  correlation  between  LV  diameter,  an  index  of  LV 
dysfunction/remodelling, and CBF, MVO2 and FFA uptake in the whole study population, 
under  basal  conditions  (Figure  5).    There  was  a  non  significant  trend  toward  a  positive 
correlation with glucose uptake (r=0.41, ns). Both under resting conditions and during pacing, 
FFA uptake (but not glucose uptake) was directly related with MVO2 (Figure 6). 
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DISCUSSION 
This study provides direct evidence for a chronic cardiac metabolic shift under both 
resting conditions and with pacing stress in DCM patients without advanced heart failure.  
This  change in cardiac metabolic profile was characterized by decreased FFA uptake and 
oxidation  and increased carbohydrate utilization, and was associated with reduced cardiac 
work, MVO2, and myocardial blood flow both at rest and in response to stress. These results 
suggest the novel view that, while the switch away from FFA oxidation in the failing heart is 
thought  to  be  compensatory  under  resting  conditions,  it  may  be  detrimental  during  even 
moderate stress, potentially contributing to progressive deterioration of myocardial function. 
Previous  studies  in  patients  with  cardiomyopathy/heart  failure  yielded  conflicting 
results.  Non invasive PET studies in non ischemic cardiomyopathy found reduced uptake and 
oxidation  of 
11C-labelled  palmitate  (35)  and/or  increased  uptake  and  utilization  of   
11C-
labelled glucose (7),
 consistent with our direct invasive measurements. However, other PET 
studies,  using  FFA  and  glucose  analogues  in  ischemic  and  non  ischemic  patients  with 
advanced  heart  failure,  found  opposite  results,  with  increased  lipids  and  decreased 
carbohydrate uptake (33, 38).
  22.  Paolisso et al evaluated myocardial energy metabolism 
in  patients with  heart failure by direct invasive measurement of transmyocardial substrate 
gradients (22), showing increased FFA utilization.  However, this study enrolled patients with 
NYHA  Class  II-III  heart  failure  of  ischemic  and  non  ischemic  origin  and  no  labelled 
substrates were used.  In the present study the patients were carefully selected to include only 
those with idiopathic dilated cardiomyopathy and without advanced heart failure to avoid the 
potential  confounding  effects  of  coronary  disease  and  of systemic  metabolic  derangement 
associated  with  cardiac  decompensation.    In  severe  heart  failure,  elevated  adrenergic 
stimulation  may  increase  MVO2 and  levels  of  FFA,  and  cardiac  insulin  resistance  may 
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develop (19).  As a consequence both fatty acid and glucose utilization may be altered and a 
condition of energy imbalance may ensue as recently discussed by Neubauer (18). 
The resting metabolic pattern that we found in DCM is similar to that observed in the 
experimental  model  of  pacing-induced  cardiomyopathy  (21,  25)  and  is  consistent  with 
findings in other animal models of progressive cardiac dysfunction and heart failure (11).  
This  shift  in  myocardial  substrate  metabolism  partially  mimics  the  neonatal  metabolic 
phenotype, with glucose and lactate instead of fatty acid being the primary energy substrate 
(31).  It remains to be determined whether these alterations are a compensatory response of the 
failing heart that optimizes cardiac energy metabolism and prevents further deterioration of 
LV  function,  or  rather  is  a  maladaptation  that  contributes  to  progression  towards 
decompensation.  Insight on this issue comes from mice with cardiac-specific over-expression 
of the insulin-independent glucose transporter GLUT1, which have increased glucose uptake 
and less contractile dysfunction and LV dilation in response to chronic pressure overload (15), 
suggesting that accelerated glucose metabolism prevents hypertension-induced heart failure.  
We observed an inverse correlation between cardiac FFA metabolism and the extent of 
LV remodelling, which was also associated with reduced MVO2, myocardial blood flow and 
cardiac work.  A primary depression of myocardial function, as can be expected in DCM, 
could cause reduced energy requirements and MVO2 and consequently reduced blood flow 
with downregulation of FFA metabolism and possible increase in carbohydrate utilization. A 
reduction  of  myocardial  oxygen  availability,  due  to  impaired  myocardial  perfusion  and 
coronary microvascular dysfunction (16, 17) and impaired oxygen utilization consequent to 
mithocondrial dysfunction (28) have been also described in DCM.  These mechanisms reduce 
energy  transduction  and  further  impair  contractility,  and  could  by  themselves  stimulate 
myocardial metabolic shift from fat oxidation to preferential utilization of carbohydrates. On 
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the other hand, a primary metabolic abnormality could exist, with lower activity of the  -
oxidation pathway (27), lowering MVO2 and causing metabolic downregulation of coronary 
flow, but also energy depletion and reduced contractile function.  
 
Myocardial metabolic response to stress in DCM 
Myocardial metabolic response to stress in DCM patients had not previously been 
investigated.  It  is  well  established  that  in  normal  hearts high rate pacing induces a rapid 
increase in glucose and lactate uptake coupled with a relative decline in FFA uptake (1, 3, 4, 
9).   Clinical and experimental studies suggest that this response is advantageous, since it 
increases myocardial mechanical efficiency as carbohydrates are a more efficient substrate 
than lipids and provides more energy for the generation of contractile power for any given  
MVO2 (20, 29, 31).  The response to pacing stress in DCM patients was very different from 
the control group:  glucose uptake, which at baseline was already elevated in DCM patient to 
levels similar to those reached in controls during stress, did not further increase. In contrast, 
FFA utilization tended to increase and the relative contribution of lipid oxidation to MVO2,
which  was  clearly  lower  in  DCM  than  in  controls  in  resting  conditions,  became  similar 
between the two groups during stress. Compared with controls, there was a lower increase in 
myocardial mechanical efficiency during pacing in the DCM patients. Taken together, these 
findings strongly indicate that there is a more limited cardiac metabolic reserve and flexibility 
in DCM.  One of the possible mechanisms explaining the metabolic rigidity of the failing 
heart  is  the  paradoxical  downregulation  of  key  enzymes  of  the  carbohydrate  oxidative 
pathway, in spite of higher glucose oxidation, that we previously described in dogs (14).  As a 
consequence, the cardiomyopathic heart must face even moderate increases in cardiac work by 
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oxidizing less efficient substrates, such as FFA, which require higher oxygen consumption 
and blood flow.  
This  abnormal  metabolic behaviour, together with impaired mitochondrial function 
(28)  and  limited  myocardial  flow  and  oxygen  availability,  possibly  due  to  coronary 
microvascular dysfunction, (16, 17) could contribute to an ischemic-like condition, (6, 36) 
enhanced oxidative stress and energy depletion in the cardiomyopathic heart. 
 
Study limitations 
The small number of both DCM and control patients, due to the strict selection criteria 
and the complexity of the protocol, limits the statistical power. A second limitation is the lack 
of a completely normal control population. Control patients had a history of angina-like chest 
pain and/or stress testing suggestive for ischemia. However, neither group of patients had the 
typical clinical and ECG pattern of syndrome X nor developed chest pain or significant ST 
segment depression during pacing stress. Since coronary catheterization procedures have an 
intrinsic risk to life, it is unethical to study a truly normal population. 
Glucose oxidation was not measured because of the significant additional adsorbed 
radiation dose to the patient.  It is important to know the effects of DCM and acute stress on 
glucose uptake and oxidation to CO2 and release of  lactate, which can only be assessed using   
14C-labelled glucose.  While the present study is the first to assess myocardial lactate kinetics 
in DCM using 
13C-lactate tracers, these studies would be greatly strengthened by dual isotopic 
studies  using 
14C-glucose/
13C-lactate  tracers  as  previously  described  (9,39).    Another 
limitation  in  the  metabolic  measurements  is  the  inability  to  measure  the  oxidation  of 
intracardiac  substrate  stores  (e.g.  glycogen  and  triglycerides),  which  likely  played  an 
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important role in supporting the increase in MVO2 in response to pacing in the DCM group 
(Figure 3). 
Diabetes was an exclusion criterion for enrolment of both DCM and control patients, 
however it cannot be excluded that the two patient populations differ in insulin resistance, and 
that this could have influenced the metabolic response to stress. Oral glucose tolerance tests 
was not performed, however BMI and the triglycerides/HDL was similar between the two 
groups, suggesting that whole body metabolic abnormalities were similar..   
According to the study protocol,  pacing moderately increased heart rate in order to 
allow tolerability in DCM patients. This choice could have caused a relatively lower increase 
in cardiac workload in normal hearts than in cardiomyopathic hearts where the effects of heart 
rate on energy expenditure are added to those of enhanced wall stress. Due to the complexity 
of the protocol we could not measure ventricular volumes to have a better estimate of actual 
workload than that provided by RPP values.  The somewhat artificial conditions of studying 
these  patients  in  the  catheterization  laboratory  and  the  use  of  heparin  likely  resulted  in 
elevated FFA in both groups. Accordingly, baseline metabolic data should be extended with 
caution to what one would see in the unheparized resting state.  It would be best to use a more 
physiological stimulus to increase MVO2, such as exercise or high dose dobutamine infusion, 
however  these  stresses  are  not  feasible  in  instrumented  patients  with  DCM  prone  to 
arrhythmias. 
Conclusions  
The  present  findings  demonstrate  that  DCM  patients  have  a  shift  in  cardiac 
metabolism  away  from  FFA  oxidation  both  at  rest  and  during  pacing  stress,  which  is 
associated with enlargement of the LV and reduced cardiac work, MVO2, and myocardial 
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blood flow.  In addition, these patients show a failure to further increase glucose uptake and 
possibly oxidative glycolysis in response to pacing stress. Our results suggest the novel view 
that, while the switch away from FFA oxidation in DCM hearts appears to be compensatory 
under  resting  conditions,  it  may  be  detrimental  during  even  moderate  stress,  potentially 
contributing to progressive deterioration of myocardial function. These findings will better 
orient therapeutic strategies aimed at modulating mitochondrial substrate oxidation in order to 
reduce symptoms and improve cardiac performance in DCM patients (2, 13). 
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Table 1. Clinical, functional and biohumoral data 
 
Controls  DCM  P value 
N 6 10   
Age  67±2  57±3  ns 
Males n (%)  3 (30)  7 (70)  ns 
Angina n (%)  5 (83)  2 (20)  p<.05 
LBBB n (%)  2 (33)  9 (90)  p<.05 
LV mass (g)  164±11  287±19  p<0.01 
NYHA class III n (%)  0  2 (20)  ns 
Functional data   
LVEF (%)  58±1  32±1  p<.001 
LVEDD (mm)  49±1  65±1  p<.001 
Neurohormonal data   
BNP (pg/ml)   21±7  91±22  p<.05 
Nt-pro-BNP (pg/ml)   123±37  593±130  p<.05 
Norepinephrine(pg/ml)  210±54  412±81  ns 
Risk factors   
Body mass index (kg/m
2) 28±2  29±2  ns 
Fasting glycemia (mg/dl)  90±4  101±9  ns 
Total triglycerides/HDL cholesterol  2.79±1.73  3.07±2.71  ns 
HDL/total cholesterol  0.23±0.02  0.24±0.02  ns 
Treatment   
Statins n (%)  3 (50)  3 (30)  ns 
Antiplatelet n (%)  2 (33)  5 (50)  ns 
Ca-antagonists n (%)  1 (17)  0  ns 
 -blockers (carvedilol) n (%)  3 (50)  6 (60)  ns 
ACE-inhibitors/AT-1 antagonists n (%)  3 (50)  9 (90)  ns 
Antialdosteronic n (%)  0  3 (30)  ns 
Diuretics n (%)  1 (17)  8 (80)  p<.05 
Digoxin n (%)  0  5 (50)  p<.05 
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Table 2. Hemodynamics 
  Controls  DCM  P value 
Heart rate (bpm)  Baseline  75±5  71±4 
Pacing  132±4  124±4 
  Recovery  77±7  71±4 
ns 
P value (Pacing vs Baseline and Recovery)    <.001  <.001    
Mean aortic pressure (mmHg)  Baseline  107±2  89±3 
Pacing  109±3  91±4 
  Recovery  105±4  90±4 
<.001 
P value (Pacing vs Baseline and Recovery)    ns  ns    
Rate-pressure product (mmHg * bpm)  Baseline  8086±590  6320±413 
Pacing  14475±642  11314±647 
  Recovery  8155±870  6438±440 
<.001 
P value (Pacing vs Baseline and Recovery)    <.001  <.001    
LAD CBF (ml/min/g)  Baseline  1.08±.07  .66±.06 
Pacing  1.19±.07  .91±.07 
  Recovery  .84±.04* .64±.07 
<.001 
P value (Pacing vs Baseline and Recovery)    ns  <.01   
*P<0.05 (Recovery vs Baseline and Pacing) 
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Table 3.  Arterial concentration of substrates.  
Controls DCM P value  
FFA (µmol/ml)  1.93±.21  1.34±.18  ns 
Glucose (µmol/ml)  5.45±.09  5.37±.31  ns 
Lactate (µmol/ml) 
 
0.51±.03  0.61±.08  ns 
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Table 4.  Percent transmyocardial net extraction of arterial FFA, glucose and lactate.  
 
Controls DCM P value
#
FFA extraction (%)  Baseline  15±5    18±10  ns 
  Pacing  12±5  15±8    ns 
  Recovery 17±6    19±12  ns 
 
Glucose extraction (%)  Baseline  1±1   4±2† <0.05 
  Pacing  2±1    2±2†* ns 
  Recovery 1±1   5±7† ns 
 
Lactate extraction (%)  Baseline  18±14   32±11‡ ns 
  Pacing  17±12   27±11‡ ns 
  Recovery 9±8   29±16‡ <0.05 
 
# DCM vs. Control under given condition.  
† p<0.05 DCM vs. Control for main effect.   
‡ p<0.001 DCM vs. Control for main effect.  
* P<0.05 compared to Baseline and Recovery.
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Figure Legends 
Figure 1. Cardiac FFA uptake and oxidation and glucose uptake in controls (black bars, n=5) 
and in DCM (slashed bars, n=10) at baseline, during atrial pacing and at recovery. * P<0.05 
pacing vs baseline and recovery; # P< 0.05 DCM vs controls. 
 
Figure 2. Cardiac net lactate uptake and tracer measured lactate uptake and release in controls 
(black bars, n=5) and in DCM (slashed bars, n=10) at baseline, during atrial pacing and at 
recovery. *P<0.05 pacing vs baseline and recovery; † P<0.05 recovery vs baseline and pacing. 
 
Figure 3. Rate pressure product (RPP, upper panel), an estimate of cardiac work, myocardial 
oxygen consumption (MVO2, middle panel) and mechanical efficiency, estimated from the 
ratio  between  RPP  and  MVO2 (lower  panel),  in  controls  (black  bars,  n=5)  and  in  DCM 
(slashed bars, n=10) at baseline, during atrial pacing and at recovery. All the values were 
corrected for myocardial mass.  *P<0.05 pacing vs baseline and recovery; # P<0.05 DCM vs 
controls. 
 
Figure 4. Percent contribution of FFA oxidation (upper panel) or lactate oxidation  (lower 
panel) to myocardial oxygen consumption (MVO2) in controls (black bars, n=5) and in DCM 
(slashed  bars,  n=10)  at  baseline,  during  atrial  pacing  and  at  recovery.  #P<0.05  DCM  vs 
controls. 
(Liao et al., 2002)
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Figure 5.  Correlations between LV end diastolic diameter (LVEDD) and resting coronary 
blood  flow  (CBF),  myocardial  oxygen  consumption  (MVO2) and  myocardial  FFA  uptake 
including controls (closed circles) and DCM patients (open circles).  
 
Figure 6. Correlations between myocardial oxygen consumption (MVO2), myocardial FFA 
and glucose uptake measured at rest and during pacing in controls (closed circles) and DCM 
patients (open circles).  
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Figure 3
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Figure 4
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Figure 6
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